`
`DEVELOPMENT
`
`TECHNIQUES TO REDUCE
`PAIN AND IRRITATION
`
`Edited by
`
`Framed K. Gupta
`
`and
`
`Gayle A Brazeau
`
`Interpharm Press
`Denver, Colorado
`
`
`
`AstraZeneca Exhibit 2087 p. 1
`InnoPharma Licensing LLC V. AstraZeneca AB IPR2017-00904
`Fresenius-Kabi USA LLC V. AstraZeneca AB IPR2017-01910
`
`
`
`Invitation to Authors
`
`dustries, please contact our director of publications.
`
`___.. Interpharm Press publishes books focused upon applied tech-
`"‘"" nology and regulatory affairs impacting healthcare manufacturv ‘
`ers worldwide. If you are considering writing or contributing to
`a book applicable to the pharmaceutical, biotechnology, medical
`device, diagnostic, cosmetic, or veterinary medicine manufacturing in-
`
`Library of Congress Cataloging~in-Publication Data
`
`Injectable drug development : techniques to reduce pain and irritation /
`edited by Pramod K. Gupta and Gayle A. Brazeau.
`p.
`cm.
`
`Includes bibliographical references and index.
`ISBN 1-5749’1—095—7
`
`‘l. Injections. 2. InjectiOnSEComplications. 3. Drug development.
`I. Gupta, Pramod K., 1959=
`. Il. Brazeau, Gayle A.
`[DNLM: 1. Injections—adverse effects. 2. Pain—chemically induced.
`3. Pain—prevention & control. 4. Pharmaceutical Preparations-m
`administration Si dosage. WB 354 156 1999]
`RM169.I49
`1999
`61526ch21
`DNLM/DLC
`
`for Library of Congress
`
`99—26911
`ClP
`
`10987654321
`
`ISBN: 1—57491~095-7
`
`Copyright © 1999 by Interpharm Press. All rights reserved.
`
`All rights reserved. This book is protected by copyright. No part of it may be re-
`produced, stored in a retrieval system, or transmitted in any form or by any
`means, electronic, mechanical, photocopying, recording, or otherwise, without
`written permission from the publisher. Printed in the United States of America.
`Where a product trademark, registration mark, or other protected mark is
`made in the text, ownership of the mark remains with the lawful owner of the
`mark. No claim, intentional or otherwise, is made by reference to any such marks
`in this book.
`
`While every effort has been made by Interpharm Press to ensure the accuracy
`of the information contained in this book, this organization accepts no responsi-
`bility for errors or omissions.
`
`Interpharm Press
`‘15 Inverness Way E.
`Englewood, CO 80112-5776, USA
`
`Phone: +1-303a662—9101
`Fax:
`+1—303—754-3953
`Orders/on-line catalog:
`wwwinterpharmcom
`
`AstraZeneca Exhibit 2087 p. 2
`
`
`
`Contents
`
`Preface
`
`Acknowledgments
`
`Editors and Contributors
`
`A: BACKGROUND OF PAIN, IRRITATION, AND/OR
`MUSCLE DAMAGE WITH INJECTABLES
`
`1.
`
`Challenges in the Development of
`Injectable Products
`
`Michael J. Akers
`
`General Challenges
`
`Safety Concerns
`
`Microbiological and Other Contamination Challenges
`
`Stability Challenges
`
`Solubility Challenges
`
`Packaging Challenges
`
`Manufacturing Challenges
`
`Delivery/Administration Challenges
`
`References
`
`xiii
`
`xiv
`
`xv
`
`3
`
`4
`
`5
`
`6
`
`8
`
`'10
`
`11
`
`11
`
`13
`
`14
`
`iii
`
`AstraZeneca Exhibit 2087 p. 3
`
`
`
`iv
`
`Injectable Drug Development
`
`Pain, Irritation, and Tissue Damage
`with Injections
`
`Wolfgang Kiement
`
`Must Injections Hurt?
`
`Mechanisms of Pain and Damage
`
`Routes of Drug Injection
`
`Cutaneous/Subcutaneous Injections
`
`18
`
`Intramuscularlnjections
`
`22
`
`Intra-aiteriallnjections
`
`24
`
`Intravenous Injections
`
`26
`
`Conclusions and Perspectives
`
`Acknowledgements
`
`References
`
`Mechanisms of Muscle Damage with
`lnjectable Products
`
`Anne McArdle and Malcolm J. Jackson
`
`Abstract
`
`Introduction
`
`Mechanisms of Muscle Damage
`
`Elevation of Intracellular Calcium Concentration
`
`58
`
`Increased Free Radical Production
`
`60
`
`Loss of Energy Homeostasis
`
`6’1
`
`Methods of Assessing Drugnlnduced Skeletal
`Muscle Damage
`
`Microscopic Analysis of Skeletal Muscle
`Muscle Function Studies
`63
`
`62
`
`Leakage of Intramuscular Proteins
`
`64
`
`Microo‘ialysis Studies of Individual Muscles
`
`64
`
`Cellular Stress Response
`
`65
`
`15
`
`’15
`
`16
`
`18
`
`49
`
`50
`
`50
`
`57
`
`57
`
`57
`
`58
`
`62
`
`Techniques to Assess the Mechanisms of Muscle Damage
`
`66
`
`Models ofMuscIe Damage
`
`66
`
`Techniques to Show Changes in Muscle Calcium Content
`
`66
`
`Markers of Increased Free Radical Activity
`
`67
`
`Methods of Measuring Cellular Energy Levels
`
`67
`
`Conclusions
`
`Acknowledgments
`
`References
`
`67
`
`57
`
`68
`
`AstraZeneca Exhibit 2087 p. 4
`
`
`
`Cantents
`
`v
`
`13: METHODS TO ASSESS FAIN; IRRITATION, AND
`MUSCLE DAMAGE FOLLUWING INJECTIONS
`
`In Vitro Methods f0? Evaluating
`Intravascular Hemolysis
`
`Jaseph F. Krzyzaniak and Samara} H. Ybikawsky
`
`Significance
`
`In Vitm Metheds for Evaluating Hemaiysis
`Static Meihmfs
`8:?
`
`Dynamfc Mamas
`
`83
`
`Comparisan of In Vitm and In Vivo Hemolysis Data
`
`Summary 0f In Vim; Methods
`
`References
`
`Lesion and Edema Models
`
`Steven C; Sui—mm
`
`Edema and Inflammation
`
`Lasian Mmfiets
`
`Rabbit
`
`92
`
`Mice
`
`95
`
`Ha?
`
`E36
`
`Biochemical'MGdeis
`
`Séarum Gfutamibflxafoafiefic fi‘ansaminas»?
`
`9?
`
`NficefyflfivGiumsamfniciasa
`
`9?
`
`Myelapemxfdase
`
`9?
`
`Craméne Kinase
`
`5:38
`
`Edema Mociels
`
`Inducing Edema
`
`$205
`
`Exudarive Modefs effnflammafion
`
`1’05
`
`Vascular Permeabflity Medals
`
`105
`
`Fom‘paci Edema Madefs
`
`106
`
`Carrelation 0f Medals
`
`Rabbi? Lesmn Vargas Rabbif Heman‘hage Scam Mode}
`
`10?
`
`Rabbit Lésion VEFSUS Rabbit CK Mada}
`
`”308
`
`Rabbit Lesion Versus Ba? 1300de Edema Model
`
`109
`
`Rabbit Lesimn Versus Raf CK Mode!
`
`120.9
`
`Rat and Humgn
`
`110
`
`'2‘?
`
`78
`
`79
`
`85
`
`86
`
`8?"
`
`9?!
`
`91
`
`93
`
`9?
`
`105
`
`“10?
`
`AstraZeneca Exhibit 2087 p. 5
`
`
`
`vi
`
`lnjectable Drug Development
`
`Models for Extended—Release Formulations
`
`Predicting Muscle Damage from
`Extended-Release Formulations
`
`1'11
`
`Future Directions
`
`Muscle Damage and CK
`
`112
`
`Gamma Scintigraphy
`
`112
`
`Electron Parametric Resenance and
`
`Nuclear Resonance Imaging
`
`112
`
`Effect ofEdema and Lesion on Bioavailability
`
`113
`
`Formulation
`
`1'13
`
`Conclusions
`
`References
`
`Rat Paw-Lick Model
`
`Pramod K. Gupta
`
`Methodology
`
`Correlation Between Rat Paw-Lick and Other
`
`Pain/Irritation Models
`
`Application of Rat Paw-Lick Model to Screening
`(Insolvent-Based Formulations
`
`Limitations of the Rat Paw-Lick Model
`
`Concluding Remarks
`
`References
`
`Radiopharmaceuticals for the Noninvasive
`Evaluation of Inflammation Following
`Intramuscular Injections
`
`Agatha Feltus, Michael Jay, and Robert M. Beihn
`
`Gamma Scintigraphy
`
`Gamma Cameras
`
`Detectors
`
`133
`
`Collimators
`
`135
`
`Electronics and Output
`
`136
`
`Computers
`
`13?
`
`Tomographic Imaging
`
`139
`
`Quality Control
`
`139
`
`Radionuclides and Radiation
`
`Scintigraphic Detection of Inflammation
`
`1’10
`
`”1‘12
`
`114
`
`1'15
`
`119
`
`120
`
`120
`
`123
`
`126
`
`128
`
`128
`
`131
`
`132
`
`’132
`
`’140
`
`141
`
`AstraZeneca Exhibit 2087 p. 6
`
`
`
`Con tents
`
`vii
`
`Gallium-67
`
`14’!
`
`Radiolabeled Leukocytes
`
`Radiolabelecl Antibodies
`
`1'43
`
`1‘45
`
`Other RadiOpharmaceuticals
`
`“l4?
`
`Summary
`
`References
`
`A Primer on In Vitro and In Vivo Cytosolic
`Enzyme Release Methods
`
`Gayle A. Brazeau
`
`Rationale for Utilizing Release of Cytosolic Components
`as a Marker of Tissue Damage
`
`Experimental Models
`
`Isolated Rodent Skeletal Muscle Model
`
`General Experimental Overview
`
`159
`
`Isolation, Extraction, and Viability of Isolated Muscles
`
`1'60
`
`Muscle Exposure to the Test Formulation
`
`162
`
`incubation Media
`
`164
`
`Cytosoiic Enzymes Utilized in Isolated Muscle Studies
`
`164
`
`Controls and Data Analysis
`
`164
`
`’148
`
`149
`
`155
`
`'15?
`
`159
`
`159
`
`Muscle Cell Culture Methods to Evaluate Muscle Injury
`
`1.65
`
`General Considerations
`
`165
`
`General Considerations in the Optimization ofEXperimental
`Cell Culture Systems
`166
`
`Selected Cell Lines in Screening for Drug-induced Toxicity
`
`168
`
`In Vivo Enzymatic Release Methods
`General Considerations
`169
`
`Animal Models
`
`170
`
`Quantification of Tissue Damage
`
`1’71
`
`Conclusions
`
`Acknowledgments
`
`References
`
`Histological and Morphological Methods
`
`Bruce M. Carlson and Robert Palmer
`
`Basic Principles Underlying Morphological Analysis
`
`Techniques of Morphological Analysis
`
`169
`
`172
`
`173
`
`17’3
`
`177
`
`179
`
`180
`
`AstraZeneca Exhibit 2087 p. 7
`
`
`
`viii
`
`Injectebie Drug Development
`
`Electron Microscopic Methods
`
`180
`
`Histological Methods
`
`183
`
`Histochemical Methods
`
`1'85
`
`lmmunocytochemicai Methods
`
`187
`
`Neuromuscular Staining Methods
`
`189
`
`Summary of Strengths and Limitations of
`Morphological Techniques in Assessing
`Muscle Damage After Injections
`
`References
`
`10.
`
`Conscious Rat Model to Assess Pain
`
`Upon Intravenous Injection
`
`John M. Mercek
`
`Experimental Procedures
`
`Experiment I
`
`Experiment 2
`
`Experiment 3
`
`Experiment 4
`
`Experiment 5
`
`Experiment 6
`
`Experiment 7
`
`196
`
`197
`
`197
`
`197
`
`197
`
`197
`
`1.98
`
`Statistical Analyses
`
`198
`
`Resolts
`
`Discussion
`
`Applications
`
`Summary and Conclusions
`
`Acknowledgments
`
`References
`
`C: APPROACHES IN THE DEVELOPMENT OF
`
`LESS-PAINFUL AND LESS-IRRITATING INJECTABLES
`
`‘11.
`
`Cosolvent Use in Injectahle Formulations
`
`Susan L. Way and Gayle Brazeau
`
`Commonly Used Solvents
`
`Polyethylene Glycols
`
`219
`
`Propylene Glycol
`
`223
`
`Ethanol
`
`225
`
`’190
`
`191
`
`193
`
`195
`
`“198
`
`204-
`
`209
`
`210
`
`211
`
`211
`
`215
`
`218
`
`AstraZeneca Exhibit 2087 p. 8
`
`
`
`Cantem‘g
`
`ix
`
`nycerm 226
`
`Cremaphom 22?
`
`228
`Benzy! Mischa!
`Amide Solvenw 23f}
`
`Dimetfiylsuffaxfide
`
`232
`
`Hemoiytic Potentia} Of Saivents/Cosolvents
`
`In Vitmfln Viva Hemalysis Campars'sous
`
`23?
`
`Muacle Damage
`
`Comment—Related Pain cm Injectien
`
`Casafvenfs Knawn t0 Gauge Pain
`
`245
`
`Methods m Minimize Pain
`
`2%?
`
`Canclusiena
`
`References
`
`12.
`
`Prodrugs
`
`Laszio Prokaf and Katalin PrakaiaTafrai
`
`Design of Fredrugs
`
`Specific: Exampies of Pradrugs Devemped if} Imprave
`Water Solubiiity of Injeciabies
`
`Anticancer Agenm 2;???
`
`Cenfra! Newaus System Agents
`
`283
`
`Other Drugs
`
`288
`
`Conaiusians
`
`Referencea
`
`13.
`
`Complexatiaanse 0f Cyclodflxtrins to
`Improve Pharmaceutical Properties of
`Intramuscular Farmulations
`
`Marcus E. Brewster and Tharsieinn Lofigsen
`
`Cyciadextrins
`
`Preparation 01“ Cycladextrin Camplexes
`
`Characterizatian 0f Cyciodextrin Complexes
`
`Use 01“ Cyclodextrins in IM Farmulatians
`
`Methodofogias
`
`319
`
`IM Taxicfty 0f Cycladaxfrins and Their Derivatéves
`
`320
`
`Use 02“ Cydadexm'ns m Repfam Toxic Excfpiems
`in {M Farmuiaz‘fans
`333
`
`Use 0f Cydadexm‘ns to Reduce Intrinsic
`Drug-8531mm Tammy
`325
`
`233
`
`2%2
`
`24,5
`
`250
`
`251
`
`26?
`
`28?
`
`273
`
`295
`
`297
`
`307
`
`AstraZeneca Exhibit 2087 p. 9
`
`
`
`lnjectable Drug Development
`
`Conclusions and Future Directions
`
`Acknowledgments
`
`References
`
`’14.
`
`Liposomal Formulations to Reduce
`Irritation of Intramuscularly and
`Subcutaneously Administered Drugs
`
`Panda Kadir, Christien Oussorcn, and Dean J. A. Crommelin
`
`Liposomes: A Short introduction
`
`Liposomes as Intramuscular and Subcutaneous
`Drug Delivery Systems
`
`Studies on Reduction of Local Irritation
`
`Studies on the Protective Effect After
`intramuscular Administration
`342
`
`Studies On the Protective Effect After inti‘adermal and
`Subcutaneous Administration
`345
`
`Discussion
`
`Conclusions
`
`References
`
`15.
`
`Biodegradable Microparticles for the
`Development of Less—Painful and
`Less-Irritating Parenterals
`
`Eiias Fattai, Fabiana Quaglia, Pramod Gupta, and Gayle Brazeau
`
`Rationale for Using Microparticles in the Development
`of Less-Painful and Less~Irritating Parenterals
`
`PolytLactide—co-Glycoiide] Microparticles as Delivery
`Systems in the Development of Less—Painful and
`
`Less-Irritating Parenterals
`
`Polymer Selection
`
`35?
`
`Microencapsulation Technique
`
`360
`
`Drug Release
`
`366
`
`Sterilization
`
`368
`
`Residual Solvents
`
`368
`
`Stability of the Encapsulated Drug and
`Micropai'ticle Products
`369
`
`329
`
`330
`
`330
`
`337
`
`338
`
`340
`
`341
`
`349
`
`350
`
`351
`
`355
`
`356
`
`357
`
`Protection Against Myotoxicity by lntramusculsrly/
`Subcutaneously Administered Microparticles
`
`370
`
`AstraZeneca Exhibit 2087 p. 10
`
`
`
`Contents
`
`xi
`
`Conclusions
`
`References
`
`16.
`
`Emulsions
`
`Framed K. Gupta and John B. Cannon
`
`Rationale for Using Emulsions for Reducing Pain and
`Irritation upon Injection
`
`Potential Mechanisms of Pain on Injection
`
`Case Studies
`
`Propofol 1’Diprivan®l
`.384
`
`382
`
`Di azepam
`Etomidaie
`
`388
`
`Pregnanolone{Eltanoione®l
`
`388
`
`Methohexital and Thiopental
`
`389
`
`AmphotericinB 390
`
`Clarithromycin
`
`391
`
`Challenges in the Use of Emulsions as Pharmaceutical
`Dosage Forms
`
`Physical Stability
`
`393
`
`Efficacy
`
`393
`
`Dose Volume
`
`394
`
`Otherlssues
`
`3.94
`
`Conclusions
`
`References
`
`D: FUTURE PERSPECTIVES IN THE DEVELOPMENT OF
`
`LESS—PAINFUL AND LessalnniTATING INJECTABLES
`
`17.
`
`Formulation and Administration Techniques
`to Minimize Injection Pain and Tissue
`Damage Associated with Parenteral Products
`
`Larry A. Gatlin and Carol A. Catlin
`
`Formulation Development
`Preformulation
`402
`
`Formulation
`
`404
`
`Focus on Osmolality, Cosolvents, Oils, and pH
`pH 4-15
`
`410
`
`371
`
`372
`
`379
`
`380
`
`381
`
`382
`
`393
`
`395
`
`395
`
`401
`
`402
`
`AstraZeneca Exhibit 2087 p. 11
`
`
`
`xii
`
`Injecmbfe Drug Development
`
`Post-meulation Precedureg
`
`pH, Additivasf and Solvents
`
`436
`
`Devices and Physicai Manipuiafims
`
`41?
`
`References
`
`Index
`
`4‘13
`
`420
`
`423
`
`AstraZeneca Exhibit 2087 p. 12
`
`
`
`1
`
`Challenges in the
`Development of lnjectable
`Products
`
`Michael J. Akers
`
`Biopharmaceuticai Products Development
`Lilly Research Laboratories
`Indianapolis, Indiana
`
`The injection of drugs is necessary either because a need exists for a very
`rapid therapeutic effect, or the drug compound is not systemically avail—
`able by non—injectable routes of administration. Early use of injections led
`
`to many adverse reactions because the needs for sterility and freedom
`from pyrogenic contamination were poorly understood [Avis 1992). Al-
`
`though Pasteur and Lister recognized the need for sterilization to eliminate
`pathogenic microorganisms during the 18603, sterilization technologies
`did not advance until much later. For example, the autoclave was discow
`
`ered in 1884, membrane filtration in 1918, ethylene oxide in 1944, high ef—
`
`ficiency particulate air (HEPA) filters in 1952, and laminar airflow in 1961.
`
`Increases in body temperature and chills in patients receiving injections
`were observed in 1911, which were feund in 1923 to be due to bacteria—
`
`produced pyrogens. The science and technology of manufacturing and us-
`
`ing injectable products have both come a long way since their inception in
`the mid-18505. However, the assurance of sterility, particularly with in—
`jectable products manufactured by aseptic manufacturing processes, con—
`
`tinues to be tremendously challenging to the parenteral drug industry.
`
`lnjectable products have some very special characteristics unlike any
`other pharmaceutical dosage form (Table 1.1}. Each of these characteristics
`offers unique challenges in the development, manufacture, testing, and use
`
`of these products. These will be discussed more specifically in later sec-
`
`tions of this chapter.
`
`AstraZeneca Exhibit 2087 p. 13
`
`
`
`4
`
`lnjectable Drug Development
`
`Table 1.1. Special Characteristics of and Requirements for Injectable
`Dosage Forms
`
`-
`
`'
`
`'
`
`0
`
`0
`
`0
`
`a
`
`Toxicologically safe—many potential formulation additives are not sufficiently safe for in-
`jectable drug administration
`
`Sterile
`
`Free from pyrogenic [including endotoxin} contamination
`
`Free from foreign particulate matter
`
`Stableanot only physically and chemically but also microbiologically
`
`Compatible with intravenous admixtures if indicated
`
`Isotonic
`
`GENERAL CHALLENGES
`
`From a formulation development standpoint, the injectable product for
`mulation must be as simple as possible. As long as there are no major
`stability, compatibility, solubility, or delivery problems with the active in
`gredient, injectable product formulation is relatively easy to accomplish.
`Ideally, the formulation will contain the active ingredient and water in a ve—
`
`hicle [e.g., sodium chloride or dextrose] that is isotonic with bodily fluid.
`Unfortunately, most active ingredients to be injected do not possess these
`ideal properties. Many drugs are only slightly soluble or are insoluble in
`aqueous media. Many drugs are unstable for extended periods of time in
`solution and even in the solid state. Some drugs are very interactive with
`surfaces such as the container/closure surface, surfaces of other formulae
`
`tion additives, or surfaces of administration devices.
`
`There are three interesting phenomena that make injectable drug for-
`
`mulation, processing and delivery so complicated compared to other phar-
`
`maceutical dosage forms:
`
`’1.
`
`There are relatively few safe and acceptable formulation addi-
`tives that can be used. If the drug has Significant stability, solu—
`
`bility, processing, contamination, and/or delivery problems, the
`
`formulation scientist does not have a plethora of formulation
`
`materials that can be used to solve these problems.
`
`2.
`
`In non-parenteral processing, because of the frequent potential
`
`for powder toxic010gy concerns, the process is set up to protect
`
`personnel from the product. In injectable product processing, the
`Opposite existsgthe process is set up to protect the product from
`
`personnel because the major sources of contamination are people.
`
`AstraZeneca Exhibit 2087 p. 14
`
`
`
`Challenges in the Development ofInjectable Products
`
`5
`
`3. When a manufacturer releases a non—injectable dosage form to
`
`the marketplace, the ultimate consumer takes that dosage form
`from its package and consumes it. Because there is little manip-
`ulation of the non-injectable dosage form, potential problems
`created by the consumer of these products are infrequent. How—
`ever, most injectable dosage forms experience one or several 8)?
`
`tra manipulations before administration to the patient. Injectable
`drug products are withdrawn from vials or ampoules, placed in
`administration devices, and/or combined with other solutions,
`
`and they are sometimes combined with other drugs. The point
`here is that something is usually done to the inj ectable product
`that can potentially affect its stability or solubility, or another
`performance factor,- such manipulations are done beyond the
`control of the manufacturer. Yet when problems occur, e.g., sta—
`bility or solubility issues, the manufacturer is responsible for
`solving them even though the manufacturer did not cause them.
`
`SAFETY CONCERNS
`
`Drug products administered by injection must be safe from two stand—
`
`points: [’1] the nature of the formulation components of the product and
`
`{2) the anatomical/physiological effects of the drug product during and af—
`ter injection.
`
`Compared to other pharmaceutical dosage forms, there are relatively
`few formulation additives a formulation scientist can choose from to solve
`
`solubility and/or stability problems, maintain sterility, achieve and main—
`
`tain isotonicity, extend or control the release of drugs from depot injec—
`tions, or accomplish some other need from a formulation standpoint [e.g.,
`bulking agent, viscosity agent, suspending/emulsifying agent). Because of
`
`the irreversibility of the injectable route of administration and the immedi—
`
`ate effect and contact of the drug product with the bloodstream and sys—
`temic circulation, any substance that has potential toxic properties, either
`
`related to the type of substance or its close, will either be unsuitable for
`
`parenteral administration or will have restrictions for the maximum
`
`amount to be in the formulation. For example, the choices of antimicrobial
`preservative agents for parenteral administration are very limited, and
`
`even those agents that are acceptable have limits on how much of the agent
`
`can be contained in a marketed dosage form. Similar restrictions exist for
`antioxidant agents, surface active agents, solubilizers, cosolvents, and
`
`other stabilizers (e.g., disodium ethylenediaminetetraacetic acid [EDTA]}.
`
`There are many potential clinical hazards that may result from the ad-
`
`ministration of drugs by injection (Duma et a1. 1992] [Table 1.2). Several of
`
`these hazards {e.g., hypersensitivity reactions, particulate matter, phlehitis]
`
`AstraZeneca Exhibit 2087 p. 15
`
`
`
`6
`
`Injectable Drug Development
`
`Table 1.2. Clinical Hazards of Parenteral Administration
`
`Air emboli
`
`-
`
`limited to IV or IA [intraerterial] usage
`
`Bleeding
`
`0
`
`Usually related to patient’s condition
`
`Fever and Toxicity
`
`4'
`
`-
`
`Local or systemic
`
`Secondary to allergic or toxic reaction
`
`Hypersensitivity
`
`9
`
`Immediate and deiayed
`
`incompatibilities
`
`'0
`
`Can be most threatening if occurring in the vascular compartment
`
`Infiltration and extravasation
`
`0
`
`Limited to IV or IA usage
`
`Overdosage
`
`°
`
`Drugs or fluids
`
`Particulate matter
`
`- Most serious in IV or IA administration
`
`6
`
`Can cause foreign body reaction
`
`Phlebitis
`
`.
`
`Usually with IV administration
`
`Sepsis
`
`' May be localized, systemic, or metastatic
`
`Thrombosis
`
`s
`
`Limited to IV or IA administration
`
`can be directly related to formulation andfor packaging components. For
`
`example, some weileknown hypersensitivity reactions exist with the use of
`bisulfites, phenol, thimerosal, parabens, and latex rubber.
`
`MICROBIOLOGICAL AND
`
`OTHER CONTAMINATION CHALLENGES
`
`There are three primary potential contamination issues to deal with. The
`first is to achieve and maintain sterility. Sterility, obviously, is the uniquely
`premier attribute of a sterile product. The concept of sterility is intriguing
`
`AstraZeneca Exhibit 2087 p. 16
`
`
`
`Challenges in the Development of Injectable Products
`
`7
`
`because it is an absolute attribute, i.e., the product is either sterile or not
`
`sterile. The achievement, maintenance, and testing of sterility involve chal~
`lenges that occupy the time, energy, and money of thousands of people and
`numerous resources. Sterility, by definition, is simplerthe absence of mi—
`
`crobial life. However, how does one prove sterility? Compendiai sterility
`tests use a very small sample from a much larger product population. How
`confident can one be of the sterility of each and every unit of product
`
`based on the test results of a very small sample size? Sterility essentially
`cannot be proved; it can only be assured. This is a huge challenge to the
`parenteral drug and device industry.
`
`Sterility can be achieved by a variety of methods, including saturated
`
`steam under pressure (the autoclave}, dry heat, gases such as ethylene ox-
`ide and vapor phase hydrogen peroxide, radiation such as cobalt 60
`gamma radiation, and aseptic filtration through at least 0.2 pun filters. Dif—
`
`ferent types of materials and products are sterilized by different methods.
`
`For example, glass containers are usually sterilized by dry heat; rubber clo—
`
`sures and filter assemblies by saturated steam under pressure; plastic and
`
`other heat labile materials by gaseous or radiation methods; and final
`product solutions either by saturated steam under pressure [if the product
`
`can withstand high temperatures], or, more commonly, by aseptic filtra-
`tion. Each of these sterilization procedures must undergo significant study
`(process validation) in order to ensure that the method is dependable to a
`
`high degree of assurance to sterilize the materiall’product in question una
`
`der normal production conditions. Great challenges exist in performing
`
`sterilization process validation and monitoring. There are also continuous
`efforts to find newer or better sterilization methods to increase the conve—
`
`nience and assurance of sterility (Akers et al. 1997].
`
`Injectable products must be fine from pyrogenic contamination. Pyroe
`gens are metabolic by-products of microbial growth and death. Pyrogenic
`contamination must be prevented since the most common sterilization
`methods [e.g., steam sterilization, aseptic filtration) cannot destroy or re—
`
`move pyrogens. Prevention can occur using solutes prepared under pyro—
`
`genic conditions, perQen-free water produced by distillation or reverse
`osmosis, pyrogen-free packaging materials where glass containers have
`
`been depyrogenated by validated dry heat sterilization methods, and rub—
`ber closures and plastic materials that have been sufficiently rinsed with
`
`pyrogen—free water. The reason for Good Manufacturing Practice (GMPl
`
`requirements for time limitations during parenteral product processing is
`
`to eliminate the potential for pyrogenic contamination, since subsequent
`sterilization of the product will remove microbial contamination but not
`
`necessarily pyrogens,
`
`In sufficient injected amounts, pyrogens can he very harmful
`
`to
`
`humans. Pyrogens are composed of lipopolysaccharides that will react with
`the hypothalamus of mammals, producing an elevation in body tempera-
`
`ture [hence its Greek roots ipym means fire and gen means beginningll.
`
`AstraZeneca Exhibit 2087 p. 17
`
`
`
`3
`
`Injeetable Drug Development
`
`Depending on the amount of pyrogen injected, other physiological prob»
`
`lems can occur, including death. Compendisl tests, both in Vivo (rabbit
`
`model) and in vitro {leulus amebocyte lysate}, are established to ensure
`
`that products used in humans are tested and (is not contain levels of pyro~
`
`gens that will tie any harm,
`
`Injectable products, if injectecl or infused as solutions, must be free
`from particulate matter contamination. Particulate matter in injectables con»
`
`notetes at least these important perceptions:
`
`”l.
`
`The degree of product quality and the subsequent reflection of
`the quality of the precinct manufacturer.
`
`2.
`
`The degree of product quality in the “customer’s” View (patient;
`
`medical prefessienal, regulatory agency).
`
`3.
`
`The Clinical implications of the potential hazards of particulate
`matter.
`
`The first two perceptionsmrelatetl to the manufacturer and to the user or
`customer—are relatively well-defined and understood in that evidence ef
`
`particulate matter will trigger a series of reactions, ranging from product
`
`complaints to product recalls and other regulatory actions, However, the
`third perception, that particulate matter is clinically hazardous, begs more
`questions and discussion. There is substantial evidence of the adverse
`physiological effects of injected particulate matter, but still much cenjec»
`ture regarding the relationship between the clinical hazard and the type,
`size, and number of particulates (Groves 1993}.
`
`STABILITY CHALLENGES
`
`lnjeetahle drugs are administered either as solutions or as dispersed sys~
`tems (suspensions, emulsions, liposemes, other micropatticulate systems}.
`The majerity of injectahle drugs have some kind of instability problem
`Many drugs that are sufficiently stable in readytomse solutions have some
`stability restrictiens such as storage in light-protected packaging systems
`or storage at refrigerated conditions, or there may be formulation ingredie-
`ents that stabilize the drug but can themselves undergo degradation.
`The Chemical stability of injectahle precincts generally involves twe
`primary routes of degradationwhydrolytie and oxidative. Other, less pree-
`dominant, Chemical degradation mechanisms of injectsble drugs involve
`racemization, photolysis, and some special types of chemical reactions oea
`curing with large molecules. A majority of injestahle drug products are too
`unstable in solution to be marketed as readyatowse solutions. Instead, they
`are available as sterile solids produced by lyophilisetion {freeze/drying) or
`sterile crystallizetienfpowder filling technologies. Drugs that can he
`
`AstraZeneca Exhibit 2087 p. 18
`
`
`
`Challenges in the Development oflnjectable Products
`
`9
`
`marketed as ready-to-use solutions or suspensions still offer the challenge
`
`of needing suitable buffer systems or antioxidant formulations for long-
`term storage stability. Freezeadried products can undergo degradation
`during the freezing and/or freeze-drying process and, therefore, require
`
`formulation additives to minimize degradation or other physical-chemical
`instability problems. Drugs sensitive to oxidation require not only suitable
`antioxidants and chelating agents in the formulation, but they also require
`special precautions during manufacturing [e.g., oxygen-free conditions),
`and Special packaging and storage conditions to protect the solution from
`
`light, high temperature, and any ingress of oxygen. Stabilization of in“
`
`jectable drugs against chemical degradation offers a huge challenge to for—
`mulation scientists.
`
`Physical stability problems are well-known for protein inj ectable
`
`dosage forms as proteins tend to self—aggregate and eventually precipitate.
`Many injectable drugs are poorly soluble and require cosolvents or solid
`additives to enhance and maintain drug solubility. However, improper
`
`storage conditions, temperature Cycling, or interactions with other com-
`ponents of the product/package system can all contribute to incompatibil—
`ities resulting, usually, in the drug falling out of solution [manifested as
`haze, crystals, or precipitate]. Again, the formulation. scientist is challenged
`with finding solutions to physical instability problems. Such solutions can
`be found with either creative formulation techniques or special handling
`
`and storage requirements.
`Microbiological issues arise with storage stability related to the con-
`tainer-closure system being capable of maintaining sterility of the product;
`the antimicrobial preservative system, if present, still meeting compendial
`
`microbial Challenge tests; and the potential for inadvertent contamination
`
`of non-terminally sterilized products and the degree of assurance that such
`
`products will not become contaminated. The concern for microbiological
`
`purity as a function of product stability has caused the Food and Drug Ad-
`ministration [FDA] and other worldwide regulatory bodies to require man-
`ufacturers of injectable products to perform sterility tests at the end of the
`
`product shelflife or to have Sufficient container-closure integrity data to
`
`ensure product sterility over the shelf life of the product.
`
`The compatibility of injectable drugs when combined with one an-
`other and/or combined with intravenous fluid diluents can create signifi-
`
`cant issues for formulation scientists. Unlike solid and semisolid dosage
`
`forms, which are used as they were released from the manufacturer, in-
`jectable dosage forms are usually manipulated by people (pharmacist,
`nurse, physician) other than the ultimate cousumer (patient) and are com«
`
`bined with other drug products and/or diluents before injection or info—
`
`sion. These manipulations and combinations are beyond the control of the
`
`manufacturer and can potentially lead to an assortment of problems.
`
`For example, faulty aseptic techniques during manipulation (e.g., reconsti~
`tution, transfer, admixture) can lead to inadvertent contamination of the
`
`AstraZeneca Exhibit 2087 p. 19
`
`
`
`10
`
`lnjectable Drug Development
`
`final product. In addition, drug combinations and additions to certain
`
`intravenous diluents can lead to physical and chemical incompatibilities. It
`
`is a great challenge to the injectable product formulator and Quality Con-
`
`trol (QC) management to anticipate these potential problems and do what—
`ever can be done to avoid or eliminate them.
`
`SOLUBILITY CHALLENGES
`
`Many drugs intended for injectable administration are not readily soluble in
`
`water. Classic examples include steroids, phenytoin, diazepam, ampho~
`
`tericin B, and digoxin. While most insolubility problems can be solved, they
`
`usually require a great amount of effort from the formulation cleveIOpment
`scientist. If a more soluble salt fOrm of the insoluble drug is not available
`
`[e.g., poor stability, difficulty in manufacture, cost, etc], then two basic for—
`
`mulation approaches can be attempted. One involves using formulation ad—
`
`clitives such as water miscible cosolvents, complexating agents {such as
`
`cyclodextrin derivatives), and surface active agents. If none of these addi-
`
`tives work, then the other approach involves the formulation of a more
`
`complex dosage form such as an emulsion or liposome. Table 1.3 lists the
`
`most common approaches for solving solubility problems with injectable
`
`drugs.
`
`Table 1.3. Approaches for increasing Solubility
`
`Salt formation [~1000X increase)
`
`pH adjustment
`
`Use of“ cosolvents {~1000X increase)
`
`Use of surface-active agents [~1OOX increase]: 6.9.. polyoxyethyiene sorbitan monooleate
`(0.1 to 0.5%) and polyoxyethylene-polyoxypropylene ethers [0.05 to 0.25%)
`
`Use of complexing agents {-600}: increase]; e.g., B—cyclodextrins and polyvinyl pyrroliclone
`(PVP)
`
`Microemulsion formulation
`
`Liposome formulation
`
`Mixed micelle formulation (bile salt + phosphollpid)
`
`”Heroic” measures: cg, for cancer clinical trial formulations, use dimethylsulfoxide
`[DMSO], high concentrations of surfactants, polyols, alcohols, fatty acids. etc.
`
`AstraZeneca Exhibit 2087 p. 20
`
`
`
`Challenges in the Development of Injectable Products
`
`'11
`
`PACKAGING CHALLENGES
`
`A formulator can create an excellent injectable formulation that is very sta—
`
`ble, easily manufacturable, and elegant. Yet the formulation must be com—
`
`patible with a packaging system. Currently, the most common injectable
`packaging systems are glass vials with rubber closures and plastic vials
`
`and bottles with rubber closures. Glass-sealed ampoules are not as popue
`
`lar as in the past because of concerns with glass breakage and particulates.
`
`Other packaging systems include glass and plastic syringes, glass bottles,
`glass cartridges, and plastic bags.
`The